表柔比星分别联合碘油与Hepasphere载药微球对肝癌患者TACE的疗效分析

摘要

Objective:To study the efficacy and prognosis of epirubicin combined with lipiodol or Hepasphere loaded microspheres in the treatment of hepatocellular carcinoma(HCC)in transcatheter arterial chemoembolization(TACE).Methods:The patients were randomly divided into two groups:Epirubicin and lipiodol(group A),epirubi-cin and Hepasphere microspheres(group B),respectively.After 1 month,the preoperative and postoperative liver and renal function,AFP,and mRECIST criteria including disease remission rate(CR+PR)and disease control rate(CR+PR+SD),and the difference between the two groups were compared.Results:In the A and B group patients before and after operation,comparison of liver and kidney function tests index values between and within groups showed no significant difference(P＞0.05).AFP before TACE in the two groups showed no significant difference(P＞0.05),and the difference was statistically significant after TACE(P＜0.05).Remission rate,control rate of two groups of patients were statistically significant(P＜0.05).Conclusion:Epirubicin combined with Hepasphere loaded micro-spheres can improve the efficacy of TACE in patients with hepatocellular carcinoma.%目的:研究表柔比星分别联合碘油与Hepasphere载药微球对经皮肝动脉化疗栓塞术(transcatheter arterial chemoembolization,TACE)治疗肝癌患者的疗效及预后分析.方法:选取病例被随机分为两组,分别注射表柔比星与碘油(A组)、表柔比星与Hepasphere微球混合液(B组).1个月后对比术前及术后肝肾功、AFP,并采用mRECIST标准[疾病缓解率(CR+PR)、疾病控制率(CR+PR+SD)]对比两组之间差别.结果:A、B组患者术前、术后肝肾功等化验指标数值,组间和组内对比无统计学差异(P＞0.05);A、B组患者TACE治疗前AFP差异无统计学意义(P＞0.05),术后AFP差异有统计学意义(P＜0.05);两组患者疾病缓解率、疾病控制率差异有统计学意义(P＜0.05).结论:表柔比星联合Hepasphere载药微球可以提高肝癌患者TACE的疗效.